MICHAELS; Mark Leo
Patent Applications and Registrations
Patent applications and USPTO patent grants for MICHAELS; Mark Leo.The latest application filed is for "pac1 antibodies and uses thereof".
Company Profile
9.26.29
- MICHAELS; Mark Leo - Encino CA
- Michaels; Mark Leo - Encinco CA
- - Encino CA US
Patent Activity
| Patent | Date |
|---|---|
| Pac1 Antibodies And Uses Thereof App 20220195022 - AGRAWAL; Neeraj Jagdish ; et al. | 2022-06-23 |
| Fg21 Mutants And Uses Thereof App 20210317176 - Belouski; Edward John ; et al. | 2021-10-14 |
| Methods of treating non-alcoholic steatohepatitis using FGF21 mutants Grant 11,072,640 - Belouski , et al. July 27, 2 | 2021-07-27 |
| Pac1 Antibodies And Uses Thereof App 20210017261 - AGRAWAL; Neeraj Jagdish ; et al. | 2021-01-21 |
| Stabilized Receptor Polypeptides And Uses Thereof App 20200283504 - SUN; Jeonghoon ; et al. | 2020-09-10 |
| Stabilized Receptor Polypeptides And Uses Thereof App 20190389932 - SUN; Jeonghoon ; et al. | 2019-12-26 |
| Pac1 Antibodies And Uses Thereof App 20190218279 - AGRAWAL; Neeraj Jagdish ; et al. | 2019-07-18 |
| Isolated nucleic acid molecules encoding stabilized receptor polypeptides and uses thereof Grant 10,308,704 - Sun , et al. | 2019-06-04 |
| Variants Of Tissue Inhibitor Of Metalloproteinase Type Three (timp-3), Compositions And Methods App 20190085054 - Sun; Jeonghoon ; et al. | 2019-03-21 |
| Variants of tissue inhibitor of metalloproteinase type three (TIMP-3), compositions and methods Grant 10,189,890 - Sun , et al. Ja | 2019-01-29 |
| FGF21 Mutants and Uses Thereof App 20190023757 - Belouski; Edward John ; et al. | 2019-01-24 |
| Methods of treating of diabetes and obesity using FGF21 mutants Grant 10,011,642 - Belouski , et al. July 3, 2 | 2018-07-03 |
| Inhibitory polypeptides specific to WNT inhibitors Grant 9,708,375 - Case , et al. July 18, 2 | 2017-07-18 |
| Stabilized Receptor Polypeptides and Uses Thereof App 20170183391 - Sun; Jeonghoon ; et al. | 2017-06-29 |
| Human FGF receptor and .beta.-Klotho binding proteins Grant 9,517,264 - Fachini , et al. December 13, 2 | 2016-12-13 |
| FGF21 mutants comprising a mutation at position 98, 171 and/or 180 Grant 9,493,530 - Belouski , et al. November 15, 2 | 2016-11-15 |
| Fgf Mutants And Uses Thereof App 20160168223 - Belouski; Edward John ; et al. | 2016-06-16 |
| Stabilized Receptor Polypeptides and Uses Thereof App 20160137718 - Sun; Jeonghoon ; et al. | 2016-05-19 |
| FGF mutants with reduced proteolysis and aggregation Grant 9,273,106 - Belouski , et al. March 1, 2 | 2016-03-01 |
| Stabilized receptor polypeptides and uses thereof Grant 9,273,114 - Sun , et al. March 1, 2 | 2016-03-01 |
| Human Antigen Binding Proteins That Bind To Proprotein Convertase Subtilisin Kexin Type 9 App 20160032014 - MICHAELS; Mark Leo ; et al. | 2016-02-04 |
| Variants Of Tissue Inhibitor Of Metalloproteinase Type Three (timp-3), Compositions And Methods App 20160031969 - Sun; Jeonghoon ; et al. | 2016-02-04 |
| Inhibitory Polypeptides Specific to WNT Inhibitors App 20160024158 - CASE; Ryan B. ; et al. | 2016-01-28 |
| Fgf21 Mutants And Uses Thereof App 20140323396 - Belouski; Edward John ; et al. | 2014-10-30 |
| FGF21 polypeptides comprising two or more mutations and uses thereof Grant 8,835,385 - Belouski , et al. September 16, 2 | 2014-09-16 |
| Fgf21 Mutants And Uses Thereof App 20140243503 - Belouski; Edward John ; et al. | 2014-08-28 |
| FGF 21 polypeptides comprising two or more mutations and uses thereof Grant 8,795,985 - Belouski , et al. August 5, 2 | 2014-08-05 |
| FGF21 mutant fusion polypeptides and uses thereof Grant 8,642,546 - Belouski , et al. February 4, 2 | 2014-02-04 |
| FGF21 mutants multimers and uses thereof Grant 08618053 - | 2013-12-31 |
| FGF21 mutants multimers and uses thereof Grant 8,618,053 - Belouski , et al. December 31, 2 | 2013-12-31 |
| Stabilized Receptor Polypeptides And Uses Thereof App 20130225484 - Sun; Jeonghoon ; et al. | 2013-08-29 |
| Human Fgf Receptor And Beta-klotho Binding Proteins App 20130129725 - Fachin ; Roger ; et al. | 2013-05-23 |
| Stabilized activin IIB receptor polypeptides and uses thereof Grant 8,410,043 - Sun , et al. April 2, 2 | 2013-04-02 |
| FGF21 mutants and uses thereof Grant 8,410,051 - Belouski , et al. April 2, 2 | 2013-04-02 |
| Uses of FGF21 polypeptides comprising two or more mutations Grant 8,361,963 - Belouski , et al. January 29, 2 | 2013-01-29 |
| Fgf21 Mutants And Uses Thereof App 20120213779 - Belouski; Edward John ; et al. | 2012-08-23 |
| Fgf21 Mutants And Uses Thereof App 20120178685 - BELOUSKI; EDWARD JOHN ; et al. | 2012-07-12 |
| Fgf21 Mutants And Uses Thereof App 20120177646 - Belouski; Edward John ; et al. | 2012-07-12 |
| FGF21 mutants and uses thereof Grant 8,188,040 - Belouski , et al. May 29, 2 | 2012-05-29 |
| Fgf21 Mutants And Uses Thereof App 20120093815 - BELOUSKI; EDWARD JOHN ; et al. | 2012-04-19 |
| Fgf21 Mutants And Uses Thereof App 20120087920 - Belouski; Edward John ; et al. | 2012-04-12 |
| Fgf21 Mutants And Uses Thereof App 20120052069 - Belouski; Edward John ; et al. | 2012-03-01 |
| Fgf21 Mutants And Uses Thereof App 20120003216 - BELOUSKI; EDWARD JOHN ; et al. | 2012-01-05 |
| FGF21 polypeptides comprising two or more mutations Grant 8,034,770 - Belouski , et al. October 11, 2 | 2011-10-11 |
| Fgf21 Mutants And Uses Thereof App 20100285131 - Belouski; Edward John ; et al. | 2010-11-11 |
| Stabilized Receptor Polypeptides And Uses Thereof App 20100168020 - Sun; Jeonghoon ; et al. | 2010-07-01 |
| FGF21 Mutants and uses thereof App 20090305986 - Belouski; Edward John ; et al. | 2009-12-10 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 